• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 5. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives

Introduction to 1H-Purine, 6-chloro-2,8-dimethyl- (CAS No. 98550-74-4)

1H-Purine, 6-chloro-2,8-dimethyl- (CAS No. 98550-74-4) is a synthetic purine derivative that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a chloro substituent at the 6-position and methyl groups at the 2 and 8 positions. These modifications contribute to its distinct chemical properties and potential biological activities.

The chemical structure of 1H-Purine, 6-chloro-2,8-dimethyl- is represented by the molecular formula C₉H₁₀ClN₃. Its molecular weight is approximately 197.65 g/mol. The compound is typically synthesized through a series of well-defined chemical reactions, including substitution and cyclization steps. The precise synthesis methods can vary, but they generally involve the use of starting materials such as purine derivatives and appropriate reagents to introduce the desired functional groups.

In recent years, 1H-Purine, 6-chloro-2,8-dimethyl- has been extensively studied for its potential therapeutic applications. One of the key areas of interest is its activity as a purinergic receptor modulator. Purinergic receptors are a class of cell surface receptors that respond to extracellular nucleotides such as ATP and ADP. These receptors play crucial roles in various physiological processes, including neurotransmission, immune responses, and vascular function.

1H-Purine, 6-chloro-2,8-dimethyl- has been shown to exhibit selective binding to specific purinergic receptor subtypes, particularly P₂X and P₂Y receptors. This selectivity makes it a valuable tool for investigating the roles of these receptors in different biological systems. For instance, studies have demonstrated that this compound can modulate pain signaling pathways by interacting with P₂X receptors in nociceptive neurons. This property has led to its evaluation as a potential analgesic agent in preclinical models of pain.

Beyond its role in pain management, 1H-Purine, 6-chloro-2,8-dimethyl- has also been explored for its anti-inflammatory effects. Inflammatory diseases such as arthritis and inflammatory bowel disease (IBD) are characterized by excessive activation of immune cells and the release of pro-inflammatory cytokines. Research has shown that 1H-Purine, 6-chloro-2,8-dimethyl- can inhibit the production of these cytokines by modulating purinergic signaling pathways in immune cells. This makes it a promising candidate for the development of novel anti-inflammatory therapies.

In addition to its pharmacological properties, the physicochemical characteristics of 1H-Purine, 6-chloro-2,8-dimethyl- are important considerations for its use in drug development. The compound is generally stable under standard laboratory conditions but may require specific storage conditions to maintain its integrity over extended periods. Its solubility properties are also critical for formulation development and delivery methods. Studies have shown that 1H-Purine, 6-chloro-2,8-dimethyl- exhibits moderate solubility in water and organic solvents, which facilitates its use in various experimental setups.

The safety profile of 1H-Purine, 6-chloro-2,8-dimethyl- has been evaluated through a series of toxicological studies. These studies have demonstrated that the compound is generally well-tolerated at therapeutic doses but may exhibit dose-dependent side effects at higher concentrations. Common side effects observed in preclinical models include mild gastrointestinal disturbances and transient changes in liver enzymes. However, these effects are typically reversible upon discontinuation of treatment.

In conclusion, 1H-Purine, 6-chloro-2,8-dimethyl- (CAS No. 98550-74-4) represents a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features and selective binding properties make it an attractive candidate for further investigation into its therapeutic potential. Ongoing research continues to explore new avenues for its use in treating various diseases and conditions, highlighting the importance of this compound in advancing our understanding of purinergic signaling pathways.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)